145 related articles for article (PubMed ID: 37678511)
21. Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive Cancers.
Odintsov I; Mattar MS; Lui AJW; Offin M; Kurzatkowski C; Delasos L; Khodos I; Asher M; Daly RM; Rekhtman N; de Stanchina E; Ganji G; Ladanyi M; Somwar R
J Thorac Oncol; 2021 Jul; 16(7):1149-1165. PubMed ID: 33839363
[TBL] [Abstract][Full Text] [Related]
22. Detection of Novel NRG1, EGFR, and MET Fusions in Lung Adenocarcinomas in the Chinese Population.
Pan Y; Zhang Y; Ye T; Zhao Y; Gao Z; Yuan H; Zheng D; Zheng S; Li H; Li Y; Jin Y; Sun Y; Chen H
J Thorac Oncol; 2019 Nov; 14(11):2003-2008. PubMed ID: 31382039
[TBL] [Abstract][Full Text] [Related]
23. ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells.
Choi BK; Fan X; Deng H; Zhang N; An Z
Cancer Med; 2012 Aug; 1(1):28-38. PubMed ID: 23342251
[TBL] [Abstract][Full Text] [Related]
24. Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer.
Jones MR; Lim H; Shen Y; Pleasance E; Ch'ng C; Reisle C; Leelakumari S; Zhao C; Yip S; Ho J; Zhong E; Ng T; Ionescu D; Schaeffer DF; Mungall AJ; Mungall KL; Zhao Y; Moore RA; Ma Y; Chia S; Ho C; Renouf DJ; Gelmon K; Jones SJM; Marra MA; Laskin J
Ann Oncol; 2017 Dec; 28(12):3092-3097. PubMed ID: 28950338
[TBL] [Abstract][Full Text] [Related]
25. Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib.
Younes M; Wu Z; Dupouy S; Lupo AM; Mourra N; Takahashi T; Fléjou JF; Trédaniel J; Régnard JF; Damotte D; Alifano M; Forgez P
Oncotarget; 2014 Sep; 5(18):8252-69. PubMed ID: 25249545
[TBL] [Abstract][Full Text] [Related]
26. NRG1-dependent activation of HER3 induces primary resistance to trastuzumab in HER2-overexpressing breast cancer cells.
Yang L; Li Y; Shen E; Cao F; Li L; Li X; Wang X; Kariminia S; Chang B; Li H; Li Q
Int J Oncol; 2017 Nov; 51(5):1553-1562. PubMed ID: 29048656
[TBL] [Abstract][Full Text] [Related]
27. RETRACTED: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor.
Brand TM; Iida M; Corrigan KL; Braverman CM; Coan JP; Flanigan BG; Stein AP; Salgia R; Rolff J; Kimple RJ; Wheeler DL
Sci Signal; 2017 Jan; 10(460):. PubMed ID: 28049763
[TBL] [Abstract][Full Text] [Related]
28. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
[TBL] [Abstract][Full Text] [Related]
29. Transcriptional activation of cyclin D1 via HER2/HER3 contributes to EGFR-TKI resistance in lung cancer.
Liu B; Chen D; Chen S; Saber A; Haisma H
Biochem Pharmacol; 2020 Aug; 178():114095. PubMed ID: 32535106
[TBL] [Abstract][Full Text] [Related]
30. Clinical significance of overexpression of NRG1 and its receptors, HER3 and HER4, in gastric cancer patients.
Yun S; Koh J; Nam SK; Park JO; Lee SM; Lee K; Lee KS; Ahn SH; Park DJ; Kim HH; Choe G; Kim WH; Lee HS
Gastric Cancer; 2018 Mar; 21(2):225-236. PubMed ID: 28573357
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series.
Cadranel J; Liu SV; Duruisseaux M; Branden E; Goto Y; Weinberg BA; Heining C; Schlenk RF; Cheema P; Jones MR; Drilon A; Trombetta D; Muscarella LA; Tolba K; Gounant V; Cseh A; Solca F; Laskin JJ; Renouf DJ
Oncologist; 2021 Jan; 26(1):7-16. PubMed ID: 32852072
[TBL] [Abstract][Full Text] [Related]
32. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
[TBL] [Abstract][Full Text] [Related]
33. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
[TBL] [Abstract][Full Text] [Related]
34. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.
Carrión-Salip D; Panosa C; Menendez JA; Puig T; Oliveras G; Pandiella A; De Llorens R; Massaguer A
Int J Oncol; 2012 Sep; 41(3):1128-38. PubMed ID: 22684500
[TBL] [Abstract][Full Text] [Related]
35. NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents.
Laskin J; Liu SV; Tolba K; Heining C; Schlenk RF; Cheema P; Cadranel J; Jones MR; Drilon A; Cseh A; Gyorffy S; Solca F; Duruisseaux M
Ann Oncol; 2020 Dec; 31(12):1693-1703. PubMed ID: 32916265
[TBL] [Abstract][Full Text] [Related]
36. Model-based analysis of HER activation in cells co-expressing EGFR, HER2 and HER3.
Shankaran H; Zhang Y; Tan Y; Resat H
PLoS Comput Biol; 2013; 9(8):e1003201. PubMed ID: 23990774
[TBL] [Abstract][Full Text] [Related]
37. The G Protein-Coupled Receptor PAC1 Regulates Transactivation of the Receptor Tyrosine Kinase HER3.
Moody TW; Lee L; Jensen RT
J Mol Neurosci; 2021 Aug; 71(8):1589-1597. PubMed ID: 32964398
[TBL] [Abstract][Full Text] [Related]
38. Mig6 not only inhibits EGFR and HER2 but also targets HER3 and HER4 in a differential specificity: Implications for targeted esophageal cancer therapy.
Zhong H; He J; Yu J; Li X; Mei Y; Hao L; Wu X
Biochimie; 2021 Nov; 190():132-142. PubMed ID: 34293452
[TBL] [Abstract][Full Text] [Related]
39. The HER family as therapeutic targets in colorectal cancer.
Ye P; Wang Y; Li R; Chen W; Wan L; Cai P
Crit Rev Oncol Hematol; 2022 Jun; 174():103681. PubMed ID: 35462030
[TBL] [Abstract][Full Text] [Related]
40. HER3/ErbB3, an emerging cancer therapeutic target.
Zhang N; Chang Y; Rios A; An Z
Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):39-48. PubMed ID: 26496898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
